APYX Q2 2026: Liposuction Momentum, Narrowed Loss, and a Steady Revenue Forecast

By a market observer channeling Matt Levine’s dry wit: APYX (Nasdaq: APYX) lays out its second-quarter results, trading clarity on top-line progress for clarity on the bottom-line pace. EPS remains a topic for later chapters, but the near-term focus is a reaffirmed revenue forecast and a product push that could reshape the company’s growth trajectory.

Overview: A quarter of steady top-line momentum and a strategic launch cadence

Apyx Medical Corporation, traded as APYX on NASDAQ, reported its second-quarter results for the period ending June 30, 2026. The company posted total revenue of $13.9 million, up 28% year over year, with the growth primarily driven by the Surgical Aesthetics segment. Surgical Aesthetics generated $12.4 million in the quarter, up from $9.7 million in the year-ago period, underscoring that the core growth engine remains in the company’s most premium domain of care.

OEM revenue came in at about $1.5 million, representing a decline of roughly 12% versus the second quarter of the prior year. The mix shift toward Surgical Aesthetics reflects a portfolio reallocating toward higher-value, consumer-facing procedures, even as the company continues to invest in broader AYON platform adoption.

On the profitability front, the company reported a net loss attributable to stockholders of $3.2 million for the quarter, improving from a $3.8 million loss in the second quarter of 2025. Adjusted EBITDA was negative by $0.7 million, versus a smaller loss of $2.0 million in the prior-year period. In short: revenue grew, losses narrowed, and meaningful profitability remains a forward-looking objective rather than this quarter’s reality.

What’s driving the quarter

Apyx highlights a strategic product cadence alongside regulatory progress. Management noted a successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in select geographies, with initial commercial shipments in June 2026. This launch target is important: it expands the AYON ecosystem beyond existing components and may act as a lever for accelerating Surgical Aesthetics adoption in upcoming quarters.

Regulatory progress also stands out. The company received expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction—an enabling step that aligns with the limited-launch narrative and the revenue mix shift. This regulatory clearance could underpin a more ambitious ramp in both hardware sales and disposables across geographies.

Management reaffirmed its full-year 2026 revenue forecast of $59.0 million to $60.0 million, signaling discipline on expectations even as the company advances its newer AYON-enabled products. The forecast provides a fence to lean on for investors evaluating the company’s path to scale, even as the market is left to infer how per-share metrics (EPS) will evolve as volume grows.

Financial snapshot and what it means for EPS and earnings expectations

The quarter’s top-line improvement sits atop a mixed-margin story. While total revenue rose, the OEM segment softened, which can weigh on gross margin dynamics if the company does not grow the higher-margin Surgical Aesthetics portion at a commensurate pace. The reported net loss of $3.2 million is a reminder that revenue expansion has not yet translated into a positive earnings per share (EPS) outcome. There is no disclosed EPS figure in the release, and market participants will be keen to see per-share data in the next quarterly filing to gauge whether the EPS consensus is moving closer to—or farther from—breakeven expectations.

The company’s narrative leaves room for an earnings surprise if the AYON-powered accelerant translates into higher gross margin or a faster mix shift toward the higher-margin devices and consumables. Absent a disclosed EPS figure, investors will monitor whether the juiced top line attaches to meaningful operating leverage as additional launches materialize.

Guidance and market expectations

The reaffirmation of the revenue forecast for 2026—$59.0 million to $60.0 million—suggests management is comfortable with the trajectory despite the ongoing losses. For readers tracking the earnings surprise potential, the absence of a stronger bottom-line read in this release means analysts will await future quarters for EPS consensus updates and any surprise on the operating margin front.

In terms of investor sentiment, the headline numbers still point toward a narrative where growth is real, but profitability remains a work in progress. The market will likely treat the guidance as a sign of disciplined commercial execution and regulatory validation, rather than a declaration of imminent profitability.

Implications for the sector and peers

The AYON platform’s expanded clearance and the limited but meaningful commercial launch of the power liposuction handpiece could set a template for how medtech firms combine regulatory milestones with early-adopter pilots to de-risk broader rollouts. For sector peers, the quarter underscores a familiar playbook: grow revenue through higher-value aesthetic devices, manage a mixed revenue stream (Surgical Aesthetics versus OEM), and chase operating leverage as you scale.

The 28% year-over-year revenue gain in the quarter—driven by Surgical Aesthetics—points to the addressable demand for enhanced aesthetic safety and efficacy, particularly when paired with platform-level systems like AYON. Yet the OEM weakness serves as a reminder that diversification across business lines remains critical. If AYON’s power liposuction adds material volume in the next several quarters, the sector could experience a shift in margin mix that supports faster profitability, provided pricing, utilization, and field execution align.

For investors tracking EPS trajectories, the quarter reinforces the idea that consensus on earnings will hinge on how quickly Ay-on’s product introductions convert into sustainable higher-margin revenue. In a broader sense, the release is a case study in the delicate balance between product development cadence, regulatory clearance, and the timing of commercial scale.

Conclusion: Progress kept on the scoreboard, profitability kept off the field—yet the clock is ticking

APYX’s Q2 2026 results reflect a company that is converting product development into a concrete growth narrative without yet delivering sustained profitability. The combination of a robust top line from Surgical Aesthetics, a limited but meaningful AYON-enabled product push, and a reaffirmed revenue forecast sets the stage for potential upside should the new handpiece launch gain scale and international traction.

As the company lobbies for broader adoption and pursues fuller integration of the AYON ecosystem, investors will be watching for EPS progress, improved gross margins, and a credible path to delivering positive EBITDA on a sustained basis. In a sector where regulatory clearance and device innovation can act as both accelerants and risk factors, APYX’s mid-2026 position is instructive: growth is real, but the climb toward profitability is still ahead.